AGF leads €13.1m round for Genticel
AGF Private Equity has led a €13.1m round for biotech business Genticel alongside three new investors: Institut Régional de Développement Industriel (IRDI), Amundi Private Equity Funds and CDC Entreprises’ InnoBio fund.
Historical investor Edmond de Rothschild Investment Partners (EdRIP), also participated in the round.
Labège-based biotech firm Genticel spun out of l¹Institut Pasteur, and until February 2010 operated under the name BT Pharma. The company employs 21 people and specialises in the development of immuno-therapeutic products aimed at preventing cervical cancers caused by the Human Papilloma Virus (HPV).
The firm's first product ProCervix will start phase I clinical trials in the second half of this year.
More on Healthcare
Gyrus Capital acquires LRE Medical from KPS-backed AIS Global
Carve-out of German diagnostic equipment manufacturer comes over two years after first sale attempt
Forbion raises combined EUR 1.35bn for venture and growth funds
Ventures Fund VI closes on EUR 750m and Growth Opportunities II on EUR 600m with both upsized by over 60%
EQT closes LSP Dementia on EUR 260m hard cap
Series A-focused fund exceeded its EUR 100m target and extended fundraising after increased LP interest in its strategy
Ardian reinvests in Neopharmed alongside NB Renaissance
French GP will move stake from fund VI to VII; additional capital allows for European M&A
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds